 Melanoma, Experimental
"Melanoma, Experimental" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.
| Descriptor ID |
D008546
|
| MeSH Number(s) |
C04.557.465.625.650.510.525 C04.557.580.625.650.510.525 C04.557.665.510.525 C04.619.600 E05.598.500.496.937
|
| Concept/Terms |
Melanoma, Experimental- Melanoma, Experimental
- Experimental Melanomas
- Melanomas, Experimental
- Experimental Melanoma
Melanoma, B16- Melanoma, B16
- B16 Melanomas
- Melanomas, B16
- B16 Melanoma
|
Below are MeSH descriptors whose meaning is more general than "Melanoma, Experimental".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Germ Cell and Embryonal [C04.557.465]
- Neuroectodermal Tumors [C04.557.465.625]
- Neuroendocrine Tumors [C04.557.465.625.650]
- Melanoma [C04.557.465.625.650.510]
- Melanoma, Experimental [C04.557.465.625.650.510.525]
- Neoplasms, Nerve Tissue [C04.557.580]
- Neuroectodermal Tumors [C04.557.580.625]
- Neuroendocrine Tumors [C04.557.580.625.650]
- Melanoma [C04.557.580.625.650.510]
- Melanoma, Experimental [C04.557.580.625.650.510.525]
- Nevi and Melanomas [C04.557.665]
- Melanoma [C04.557.665.510]
- Melanoma, Experimental [C04.557.665.510.525]
- Neoplasms, Experimental [C04.619]
- Melanoma, Experimental [C04.619.600]
- Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
- Investigative Techniques [E05]
- Models, Animal [E05.598]
- Disease Models, Animal [E05.598.500]
- Neoplasms, Experimental [E05.598.500.496]
- Melanoma, Experimental [E05.598.500.496.937]
Below are MeSH descriptors whose meaning is more specific than "Melanoma, Experimental".
This graph shows the total number of publications written about "Melanoma, Experimental" by people in this website by year, and whether "Melanoma, Experimental" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 1 | 0 | 1 | | 1991 | 1 | 0 | 1 | | 1994 | 1 | 0 | 1 | | 2001 | 2 | 0 | 2 | | 2002 | 1 | 1 | 2 | | 2003 | 2 | 0 | 2 | | 2005 | 2 | 0 | 2 | | 2006 | 2 | 0 | 2 | | 2007 | 0 | 2 | 2 | | 2008 | 3 | 0 | 3 | | 2009 | 0 | 2 | 2 | | 2010 | 1 | 0 | 1 | | 2011 | 4 | 2 | 6 | | 2012 | 4 | 2 | 6 | | 2013 | 2 | 2 | 4 | | 2014 | 4 | 2 | 6 | | 2015 | 5 | 2 | 7 | | 2016 | 1 | 4 | 5 | | 2017 | 2 | 1 | 3 | | 2018 | 0 | 2 | 2 | | 2019 | 4 | 0 | 4 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Melanoma, Experimental" by people in Profiles.
-
Basher F, Dhar P, Wang X, Wainwright DA, Zhang B, Sosman J, Ji Z, Wu JD. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. J Hematol Oncol. 2020 06 09; 13(1):74.
-
Williford JM, Ishihara J, Ishihara A, Mansurov A, Hosseinchi P, Marchell TM, Potin L, Swartz MA, Hubbell JA. Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy. Sci Adv. 2019 12; 5(12):eaay1357.
-
Ishihara J, Ishihara A, Sasaki K, Lee SS, Williford JM, Yasui M, Abe H, Potin L, Hosseinchi P, Fukunaga K, Raczy MM, Gray LT, Mansurov A, Katsumata K, Fukayama M, Kron SJ, Swartz MA, Hubbell JA. Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci Transl Med. 2019 04 10; 11(487).
-
Botelho NK, Tschumi BO, Hubbell JA, Swartz MA, Donda A, Romero P. Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control. Front Immunol. 2019; 10:294.
-
Khot A, Matsueda S, Thomas VA, Koya RC, Shah DK. Measurement and Quantitative Characterization of Whole-Body Pharmacokinetics of Exogenously Administered T Cells in Mice. J Pharmacol Exp Ther. 2019 03; 368(3):503-513.
-
Hou Y, Liang H, Rao E, Zheng W, Huang X, Deng L, Zhang Y, Yu X, Xu M, Mauceri H, Arina A, Weichselbaum RR, Fu YX. Non-canonical NF-?B Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy. Immunity. 2018 09 18; 49(3):490-503.e4.
-
Ishihara J, Ishihara A, Potin L, Hosseinchi P, Fukunaga K, Damo M, Gajewski TF, Swartz MA, Hubbell JA. Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity. Mol Cancer Ther. 2018 11; 17(11):2399-2411.
-
Ishihara J, Fukunaga K, Ishihara A, Larsson HM, Potin L, Hosseinchi P, Galliverti G, Swartz MA, Hubbell JA. Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Sci Transl Med. 2017 Nov 08; 9(415).
-
Horton BL, Williams JB, Cabanov A, Spranger S, Gajewski TF. Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. Cancer Immunol Res. 2018 01; 6(1):14-24.
-
Fankhauser M, Broggi MAS, Potin L, Bordry N, Jeanbart L, Lund AW, Da Costa E, Hauert S, Rincon-Restrepo M, Tremblay C, Cabello E, Homicsko K, Michielin O, Hanahan D, Speiser DE, Swartz MA. Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma. Sci Transl Med. 2017 Sep 13; 9(407).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|